The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

May. 04, 2020
Applicants:

Vib Vzw, Ghent, BE;

Universiteit Gent, Ghent, BE;

Centre National DE LA Recherche Scientifique, Paris, FR;

Université DE Montpellier, Montpellier, FR;

Centre Hospitalier Regional Universitaire DE Montpellier, Montpellier, FR;

Inventors:

Jan Tavernier, Balegem, BE;

Jennyfer Bultinck, Ledeberg, BE;

Frank Peelman, Gentbrugge, BE;

Gilles Uze, Montpellier, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/525 (2006.01); C07K 16/32 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/525 (2013.01); C07K 16/2869 (2013.01); C07K 16/32 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/569 (2013.01); C07K 2319/00 (2013.01); C07K 2319/74 (2013.01);
Abstract

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.


Find Patent Forward Citations

Loading…